Switching from adalimumab originator to biosimilar: a 3-year retrospective cohort analysis

被引：0
|
作者：
Killion, Lisa [1 ]
Alsharqi, Ali [1 ]
Kirby, Brian [1 ]
机构：
[1] St Vincents Hosp, Dublin, Ireland
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2023年 / 188卷
关键词：
D O I：
10.1093/bjd/ljad113.113
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P85
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Comparable drug levels and immunogenicity in patients with axial spondyloarthritis treated with adalimumab originator and biosimilar: A retrospective study from two centers of China
    Fu, Zhong-Chao
    Cheng, Xiao-Gui
    Zhang, Guo-Wen
    Shi, Ran-Geng
    Zhang, Li-Jun
    Sun, Hai-Tian
    Huang, Jin-Xian
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2024, 27 (05)
  • [42] BUPROPION OVERDOSE - A 3-YEAR MULTICENTER RETROSPECTIVE ANALYSIS
    SPILLER, HA
    RAMOSKA, EA
    KRENZELOK, EP
    SHEEN, SR
    BORYS, DJ
    VILLALOBOS, D
    MUIR, S
    JONESEASOM, L
    AMERICAN JOURNAL OF EMERGENCY MEDICINE, 1994, 12 (01): : 43 - 45
  • [43] Non-pharmacological Effects in Switching Medication: The Nocebo Effect in Switching from Originator to Biosimilar Agent
    Kristensen, Lars Erik
    Alten, Rieke
    Puig, Luis
    Philipp, Sandra
    Kvien, Tore K.
    Mangues, Maria Antonia
    van den Hoogen, Frank
    Pavelka, Karel
    Vulto, Arnold G.
    BIODRUGS, 2018, 32 (05) : 397 - 404
  • [44] Non-pharmacological Effects in Switching Medication: The Nocebo Effect in Switching from Originator to Biosimilar Agent
    Lars Erik Kristensen
    Rieke Alten
    Luis Puig
    Sandra Philipp
    Tore K. Kvien
    Maria Antonia Mangues
    Frank van den Hoogen
    Karel Pavelka
    Arnold G. Vulto
    BioDrugs, 2018, 32 : 397 - 404
  • [45] Switching Australian patients with moderate to severe inflammatory bowel disease from originator to biosimilar infliximab: a multicentre, parallel cohort study
    Haifer, Craig
    Srinivasan, Ashish
    An, Yoon-Kyo
    Picardo, Sherman
    van Langenberg, Daniel
    Menon, Shankar
    Begun, Jakob
    Ghaly, Simon
    Thin, Lena
    MEDICAL JOURNAL OF AUSTRALIA, 2021, 214 (03) : 128 - +
  • [46] OUTCOMES FOLLOWING SWITCHING FROM ORIGINATOR TO BIOSIMILAR PRODUCT IN CHILDREN AND YOUNG PEOPLE WITH JIA
    Kearsley-Fleet, Lianne
    Baildam, Eileen
    Beresford, Michael W.
    Douglas, Sharon
    Foster, Helen E.
    Southwood, Taunton R.
    Hyrich, Kimme L.
    RHEUMATOLOGY, 2023, 62
  • [47] REAL-WORLD EXPERIENCE OF SWITCHING FROM ORIGINATOR TO BIOSIMILAR RITUXIMAB IN RHEUMATOID ARTHRITIS
    Melville, A.
    Yusof, M. Y. Md
    Fitton, J.
    Bailey, L.
    Emery, P.
    Buch, M. H.
    Dass, S.
    Saleem, B.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 299 - 300
  • [48] Switching From Originator to Biosimilar Infliximab in Paediatric Inflammatory Bowel Disease Is Feasible and Uneventful
    Gervais, Lisa
    McLean, Luke L.
    Wilson, Michelle L.
    Cameron, Carol
    Curtis, Lee
    Garrick, Vikki
    Armstrong, Kat
    Tayler, Rachel
    Henderson, Paul
    Hansen, Richard
    Chalmers, Iain
    Wilson, David C.
    Russell, Richard K.
    JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2018, 67 (06): : 745 - 748
  • [49] Effectiveness and safety of Adalimumab switch from originator to biosimilar in patients with inflammatory bowel disease in clinical remission
    Gros, B.
    Soto Escribano, P.
    Marin Pedrosa, S.
    Medina Medina, R.
    Benitez, J. M.
    Iglesias-Flores, E.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I486 - I486
  • [50] THE RESOURCE COST OF SWITCHING STABLE RHEUMATOLOGY PATIENTS FROM AN ORIGINATOR BIOLOGIC TO A BIOSIMILAR IN THE UK
    Barnes, T.
    Wong, E.
    Thakrar, K.
    Glen, F.
    Young-Min, S.
    Marchbank, K.
    Ingram, A.
    VALUE IN HEALTH, 2017, 20 (09) : A543 - A543
12345